TECH Bio-Techne Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TECH

Price (delayed)

$72.83

Market cap

$11.44B

P/E Ratio

66.21

Dividend/share

$0.32

EPS

$1.1

Enterprise value

$11.38B

?
Relative Growth: Rel. Growth: 47
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: 26
Relative Profitability: Rel. Profitability: 87

Contact: David Clair, Senior Director, Corporate Development [email protected] 612-656-4416 SOURCE Bio-Techne Corporation Related Links https://www.bio-techne.com/

Highlights
Bio-Techne's debt has decreased by 28% YoY
TECH's P/E is 15% below its last 4 quarters average of 78.2 and 3.9% below its 5-year quarterly average of 68.9
The net income has soared by 121% YoY but it has decreased by 5% from the previous quarter
TECH's EPS has surged by 120% year-on-year but it is down by 6% since the previous quarter
The quick ratio has declined by 48% since the previous quarter and by 33% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.bio-techne.com
Peers: TMO DHR QGEN BDX

Key stats

What are the main financial stats of TECH

TECH stock price

How has the Bio-Techne stock price performed over time
Intraday
0.04%
1 week
0.23%
1 month
0.37%
1 year
18.62%
YTD
23.84%
QTD
0.5%

Financial performance

How have Bio-Techne's revenue and profit performed over time
Revenue
$1.23B
Gross profit
$807.58M
Operating income
$240.84M
Net income
$171.97M
Gross margin
65.8%
Net margin
14%
The net income has soared by 121% YoY but it has decreased by 5% from the previous quarter
Bio-Techne's net margin has surged by 119% YoY but it has decreased by 7% QoQ
The company's operating income has surged by 119% YoY but it fell by 4.4% QoQ
Bio-Techne's operating margin has surged by 118% YoY but it has decreased by 5% QoQ

Price vs fundamentals

How does TECH's price correlate with its fundamentals

Growth

What is Bio-Techne's growth rate over time

Valuation

What is Bio-Techne stock price valuation
TECH P/E details
P/E
66.21
P/B
5.27
P/S
9.3
EV/EBIT
48
EV/EBITDA
34.09
EV/Sales
9.26
TECH's EPS has surged by 120% year-on-year but it is down by 6% since the previous quarter
TECH's P/E is 15% below its last 4 quarters average of 78.2 and 3.9% below its 5-year quarterly average of 68.9
The stock's price to book (P/B) is 14% less than its 5-year quarterly average of 6.1 but 12% more than its last 4 quarters average of 4.7
Bio-Techne's equity has increased by 10% YoY and by 2.7% from the previous quarter
The price to sales (P/S) is 13% higher than the last 4 quarters average of 8.2 but 9% lower than the 5-year quarterly average of 10.2

Efficiency

How efficient is Bio-Techne business performance
Bio-Techne's ROIC has soared by 140% YoY and by 2.5% from the previous quarter
TECH's return on assets has surged by 123% year-on-year but it is down by 6% since the previous quarter
Bio-Techne's return on equity has surged by 110% YoY but it has decreased by 8% QoQ
TECH's return on sales has surged by 105% year-on-year but it is down by 6% since the previous quarter

Dividends

What is TECH's dividend history
Dividend details
DPS
$0.32
Dividend yield
0.44%
Payout ratio
29.1%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Bio-Techne financials performed over time
TECH's current ratio is down by 50% from the previous quarter and by 46% YoY
The quick ratio has declined by 48% since the previous quarter and by 33% year-on-year
Bio-Techne's debt is 87% lower than its equity
TECH's debt to equity is down by 35% year-on-year and by 7% since the previous quarter
Bio-Techne's debt has decreased by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.